PARATEK PHARMACEUTICALS

Lobbying for PARATEK PHARMACEUTICALS · Pharmaceuticals - Antibiotics & Biodefense

Filing Registration

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Mar 13, 2025

Money reported

None

Registrations and no-activity reports carry no figure.

Client based in

Pennsylvania

Lobbying activity 4

Defense

FY 2026 Appropriations for DOD and HHS, focused on funding for development and procurement of medical countermeasures and antibiotics.

Health Issues

FY 2026 Appropriations for DOD and HHS, focused on funding for development and procurement of medical countermeasures and antibiotics.

Disaster Planning/Emergencies

FY 2026 Appropriations for DOD and HHS, focused on funding for development and procurement of medical countermeasures and antibiotics.

Homeland Security

FY 2026 Appropriations for DOD and HHS, focused on funding for development and procurement of medical countermeasures and antibiotics.

Foreign interests disclosed 3

Section 7 of the LD-2: foreign entities that own part of the client, paid toward this lobbying, or stand to benefit from it.

B-FLEXION GROUP HOLDINGS

Switzerland · Geneva · owns 80% of the client · contributed $0.00
B-FLEXION INTERNATIONAL HOLDINGS SA

Switzerland · Geneva · owns 80% of the client · contributed $0.00
ERNESTO BERTARELLI

Switzerland · Geneva · owns 80% of the client · contributed $0.00

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.